Chlorite In the Treatment of Acute Respiratory Distress Syndrome
OwnerMichael S. McGrathinventor
Life of this patent
Estimating the term…
Loading patent…
OwnerMichael S. McGrathinventor
Estimating the term…
Disclosed herein are methods of treating a subject having, or at risk of developing, acute respiratory distress syndrome (ARDS) by administering a chlorite composition in an amount effective to treat the subject. Aspects of the methods also include administering a chlorite formulation to a subject having or suspected of having a coronavirus infection, e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome (SARS-CoV), or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Also disclosed herein are methods of regulating macrophage activity in a subject having, or at risk of developing ARDS by contacting a macrophage of a subject having or at risk of developing ARDS with a chlorite composition in an amount effective to regulate one or more functional properties of the macrophage. The disclosure also features methods of determining inhibition of a ARDS-induced macrophage activity by a chlorite agent.
A method of treating a subject having or at risk of developing acute respiratory distress syndrome (ARDS), the method comprising:
The method of claim 3, wherein the chlorite salt is sodium chlorite.
A method of treating a subject having or suspected of having a coronavirus infection, the method comprising:
A method of regulating macrophage activity in a subject having or at risk of developing an acute respiratory distress syndrome (ARDS), comprising:
23a. The method of claim 19, wherein the functional property is a soluble plasma factor associated with one or more of cellular activation, inflammation, and infiltration of bacteria, and the contacting decreases the level of the soluble plasma factor activity as measured in the blood.
23b. The method of claim 23a, wherein the soluble plasma factor is C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10), interleukin-1 receptor antagonist (IL1Ra), hepatocyte growth factor (HGF), sCD163, osteopontin (OPN), or a combination thereof.
23c. The method of claim 19, wherein the functional property is a nuclear factor- κB (NF-κB), and the contacting decreases the NF-κB activity as measured in the blood.
A method of determining inhibition of an acute respiratory distress syndrome (ARDS)-induced macrophage activity by a chlorite agent, comprising:
Dependencies are inferred from the claim text.